simparica trio
zoetis belgium s.a. - ožkos, sarolaner, pyrantel embonate - antiparasitics - Šunys - Šunims, arba gresia, sumaišyti išorės ir vidaus parazitinės invazijos. veterinarinis vaistas yra tik nurodyta, kada naudoti nuo erkių ar blusų ir virškinimo trakto nematodų yra nurodyta, tuo pačiu metu. veterinarinio vaisto taip pat numatyta, vienalaikio veiksmingumo prevencijos heartworm ligos ir angiostrongylosis. ectoparasitesfor gydymas, erkių antplūdžio. veterinarinio vaisto turi nedelsiant ir nuolat erkių žuvo veikla 5 savaites prieš ixodes hexagonus, ixodes ricinus ir rhipicephalus sanguineus ir 4 savaites prieš dermacentor reticulatus;gydymas nuo blusų antplūdis (ctenocephalides felis ir ctenocephalides canis). veterinarinio vaisto turi nedelsiant ir nuolat blusų žuvo veiklą nuo naujos invazijos 5 savaites;veterinarinis vaistas gali būti naudojamas kaip dalis gydymo kontrolės strategija, alergijos blusų dermatitas (fad). virškinimo trakto nematodesfor gydyti virškinimo trakto roundworm ir hookworm infekcijos:toxocara canis nesubrendęs suaugusiems (l5) ir suaugusiems;ancylostoma caninum l4 lervos, nesubrendęs suaugusiems (l5) ir suaugusiems;toxascaris leonina suaugusiems;uncinaria stenocephala suaugusieji. kiti nematodesfor prevencijos heartworm ligos (dirofilaria immitis);prevencijos angiostrongylosis sumažinti infekcijos lygį su nesubrendęs suaugusiųjų (l5) etapais angiostrongylus vasorum.
duloxetine lilly
eli lilly nederland b.v. - duloksetinas - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly yra nurodyta suaugusiems:gydant didžiosios depresijos disordertreatment cukriniu diabetu periferinis neuropatinis paintreatment, generalizuoto nerimo disorderduloxetine lilly yra nurodyta suaugusieji.
ultomiris
alexion europe sas - ravulizumab - hemoglobinurija, paroksizminis - selektyvūs imunosupresantai - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresantai - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresantai - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - kiti antiepileptics - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
aservo equihaler
boehringer ingelheim vetmedica gmbh - ciclesonide - kvėpavimo sistemos, kiti vaistai nuo obstrukcinių kvėpavimo takų ligų, inhalants - arkliai - siekiant palengvinti klinikiniai požymiai sunkių arklių astma (anksčiau žinomas kaip pasikartojantys kvėpavimo takų obstrukcija – (rao), vasaros ganyklų susijęs periodinis kvėpavimo takų obstrukcija – (spa-rao)).
flavamed
berlin-chemie ag (menarini group) - ambroksolio hidrochloridas - šnypščiosios tabletės - 60 mg; 30 mg - ambroxol
desmopressin sumar
sumar pharma ehf - desmopresinas - poliežuvinės tabletės - 120 µg - desmopressin
sildenafil ingen pharma
sia ingen pharma - sildenafilis - plėvele dengtos tabletės - 100 mg; 50 mg - sildenafil